Rolls-Royce enthusiasts are eagerly anticipating the unveiling of the facelifted 2025 Rolls-Royce Cullinan Series II, the ...

Various agencies, such as the Department of Home Affairs and Labour, the Gauteng Traffic Department, the TMPD, CPFs and ...

Cullinan plans to exclusively pursue development of its T-cell-engager CLN-978 in autoimmune disorders, beginning as a ...

CAMBRIDGE, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic ...

Cullinan Oncology, now renamed Cullinan Therapeutics, is riding the growing wave of interest in autoimmune disorders by ...

Cullinan shifts focus to autoimmune diseases with CLN-978, targeting systemic lupus erythematosus. Initial trial results show ...

Cullinan Therapeutics, Inc. (CGEM) announced the appointment of Mary Kay Fenton as Chief Financial Officer, effective April ...

Bradley Canino, an analyst from Stifel Nicolaus, has initiated a new Buy rating on Cullinan Management (CGEM). Bradley Canino has given his Buy rating due to a combination of factors related to ...

Cullinan Therapeutics (CGEM) stock surges as William Blair touts its lymphoma candidate, CLN-978, following data for a similar drug from Amgen (AMGN). Read more here.

The findings have implications for Cullinan Therapeutics Inc’s (NASDAQ:CGEM) CLN-978, a similar CD19xCD3 bispecific T-cell engager. Most recently, Cullinan Therapeutics, formerly Cullinan ...

Mixed-use properties have matured as communities, shoppers and end-users have realized the benefits they offer. While many ...

By Colin Kellaher Cullinan Therapeutics has named Mary Kay Fenton chief financial officer, taking over from Jeff Trigilio effective Monday. Cullinan ...